175 related articles for article (PubMed ID: 23010687)
21. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
[TBL] [Abstract][Full Text] [Related]
22. Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn's disease?
Bhalme M; Sharma A; Keld R; Willert R; Campbell S
Eur J Gastroenterol Hepatol; 2013 May; 25(5):543-9. PubMed ID: 23337170
[TBL] [Abstract][Full Text] [Related]
23. Combined modality treatment for complex fistulating perianal Crohn's disease.
Antakia R; Shorthouse AJ; Robinson K; Lobo AJ
Colorectal Dis; 2013 Feb; 15(2):210-6. PubMed ID: 22672653
[TBL] [Abstract][Full Text] [Related]
24. 12-month follow-up after successful infliximab therapy in pediatric crohn disease.
Wynands J; Belbouab R; Candon S; Talbotec C; Mougenot JF; Chatenoud L; Schmitz J; Cézard JP; Goulet O; Hugot JP; Ruemmele FM
J Pediatr Gastroenterol Nutr; 2008 Mar; 46(3):293-8. PubMed ID: 18376247
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
Warman A; Straathof JW; Derijks LJ
Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
[TBL] [Abstract][Full Text] [Related]
26. [Therapeutic effects of combined enteral nutrition with Tripterygium Wilfordii poly-glycoside in remission induction of active adult Crohn's disease].
Gong JF; Niu LY; Wei XW; Zhu WM; Li N; Li JS
Zhonghua Wai Ke Za Zhi; 2009 Aug; 47(16):1213-7. PubMed ID: 19781164
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic strategy for Crohn's disease with a loss of response to infliximab: a single-center retrospective study.
Nagata Y; Esaki M; Umeno J; Fuyuno Y; Ikegami K; Maehata Y; Asano K; Moriyama T; Nakamura S; Kitazono T; Matsumoto T
Digestion; 2015; 91(1):50-6. PubMed ID: 25632918
[TBL] [Abstract][Full Text] [Related]
28. eHealth: individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn’s disease.
Pedersen N; Elkjaer M; Duricova D; Burisch J; Dobrzanski C; Andersen NN; Jess T; Bendtsen F; Langholz E; Leotta S; Knudsen T; Thorsgaard N; Munkholm P
Aliment Pharmacol Ther; 2012 Nov; 36(9):840-9. PubMed ID: 22971016
[TBL] [Abstract][Full Text] [Related]
29. Enteral nutrition decreases hospitalization rate in patients with Crohn's disease.
Watanabe O; Ando T; Ishiguro K; Takahashi H; Ishikawa D; Miyake N; Kato T; Hibi S; Mimura S; Nakamura M; Miyahara R; Ohmiya N; Niwa Y; Goto H
J Gastroenterol Hepatol; 2010 May; 25 Suppl 1():S134-7. PubMed ID: 20586855
[TBL] [Abstract][Full Text] [Related]
30. A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease.
Vahabnezhad E; Rabizadeh S; Dubinsky MC
Inflamm Bowel Dis; 2014 Apr; 20(4):606-13. PubMed ID: 24552827
[TBL] [Abstract][Full Text] [Related]
31. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease.
Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Ainsworth MA
Scand J Gastroenterol; 2011 Mar; 46(3):310-8. PubMed ID: 21087119
[TBL] [Abstract][Full Text] [Related]
32. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial.
Yoshida K; Fukunaga K; Ikeuchi H; Kamikozuru K; Hida N; Ohda Y; Yokoyama Y; Iimuro M; Takeda N; Kato K; Kikuyama R; Nagase K; Hori K; Nakamura S; Miwa H; Matsumoto T
Inflamm Bowel Dis; 2012 Sep; 18(9):1617-23. PubMed ID: 22081474
[TBL] [Abstract][Full Text] [Related]
33. Role of TNFRSF1B polymorphisms in the response of Crohn's disease patients to infliximab.
Medrano LM; Taxonera C; Márquez A; Barreiro-de Acosta M; Gómez-García M; González-Artacho C; Pérez-Calle JL; Bermejo F; Lopez-Sanromán A; Martín Arranz MD; Gisbert JP; Mendoza JL; Martín J; Urcelay E; Núñez C
Hum Immunol; 2014 Jan; 75(1):71-5. PubMed ID: 24121042
[TBL] [Abstract][Full Text] [Related]
34. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients.
Bultman E; de Haar C; van Liere-Baron A; Verhoog H; West RL; Kuipers EJ; Zelinkova Z; van der Woude CJ
Aliment Pharmacol Ther; 2012 Feb; 35(3):335-41. PubMed ID: 22191671
[TBL] [Abstract][Full Text] [Related]
35. [Long-term outcome of infliximab therapy in pediatric Crohn disease].
Wanty C; Stephenne X; Sokal E; Smets F
Arch Pediatr; 2011 Aug; 18(8):863-9. PubMed ID: 21723101
[TBL] [Abstract][Full Text] [Related]
36. Factors affecting recurrence in patients with Crohn's disease under nutritional therapy.
Esaki M; Matsumoto T; Nakamura S; Yada S; Fujisawa K; Jo Y; Iida M
Dis Colon Rectum; 2006 Oct; 49(10 Suppl):S68-74. PubMed ID: 17106818
[TBL] [Abstract][Full Text] [Related]
37. High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment.
Magro F; Rodrigues-Pinto E; Santos-Antunes J; Vilas-Boas F; Lopes S; Nunes A; Camila-Dias C; Macedo G
J Crohns Colitis; 2014 Feb; 8(2):129-36. PubMed ID: 23932786
[TBL] [Abstract][Full Text] [Related]
38. A prospective open-label trial of Remicade in patients with severe exacerbation of Crohn's disease requiring hospitalization: a comparison with outcomes previously observed in patients receiving intravenous hydrocortisone.
Bhatia JK; Korelitz BI; Panagopoulos G; Lobel E; Mirsky F; Sultan K; DiSanti W; Chun A; Keenan G; Mamun K
J Clin Gastroenterol; 2007 Aug; 41(7):677-81. PubMed ID: 17667052
[TBL] [Abstract][Full Text] [Related]
39. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
[TBL] [Abstract][Full Text] [Related]
40. Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease.
Steenholdt C; Palarasah Y; Bendtzen K; Teisner A; Brynskov J; Teisner B; Nielsen CH
Aliment Pharmacol Ther; 2013 Jun; 37(12):1172-83. PubMed ID: 23650912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]